Cargando…

An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2

The clinical utility of human interleukin-2 (hIL-2) is limited by its short serum half-life, preferential activation of regulatory T (T(Reg)) over immune effector cells, and dose-limiting toxicities. We previously engineered F10 immunocytokine (IC), an intramolecularly assembled cytokine/antibody fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silver, Aliyah B., Tzeng, Stephany Y., Lager, Mallory, Wang, Jeremy, Ishihara, Jun, Green, Jordan J., Spangler, Jamie B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10694763/ https://www.ncbi.nlm.nih.gov/pubmed/37992685 http://dx.doi.org/10.1016/j.xcrm.2023.101289

Ejemplares similares

Evaluation of novel immunocytokines that preferentially target high or intermediate affinity IL-2 receptors
por: Perez Horta, Zulmarie, et al.
Publicado: (2014)

NHS-IL12, a Tumor-Targeting Immunocytokine
por: Greiner, John W, et al.
Publicado: (2021)

The immunocytokine NHS-IL12 as a potential cancer therapeutic
por: Fallon, Jonathan, et al.
Publicado: (2014)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
por: Jung, Keunok, et al.
Publicado: (2022)

Utilizing Immunocytokines for Cancer Therapy
por: Runbeck, Erin, et al.
Publicado: (2021)

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
por: Klein, Christian, et al.
Publicado: (2017)

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer
por: Klein, C
Publicado: (2014)

The present and future of immunocytokines for cancer treatment
por: Gout, Dennis Y., et al.
Publicado: (2022)

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis
por: Schwager, Kathrin, et al.
Publicado: (2009)

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
por: Sondel, Paul M., et al.
Publicado: (2012)

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
por: Vincent, Marie, et al.
Publicado: (2013)

Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
por: Rekers, Nicolle H, et al.
Publicado: (2015)

Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma
por: Paoloni, Melissa, et al.
Publicado: (2015)

Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?
por: van de Loo, Fons A, et al.
Publicado: (2009)

Novel Immunocytokine IL12-SS1 (Fv) Inhibits Mesothelioma Tumor Growth in Nude Mice
por: Kim, Heungnam, et al.
Publicado: (2013)

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12
por: Morillon, Y. Maurice, et al.
Publicado: (2019)

Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
por: Kujawski, Maciej, et al.
Publicado: (2020)

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
por: Waldhauer, Inja, et al.
Publicado: (2021)

Immunocytokines: a review of molecules in clinical development for cancer therapy
por: List, Thomas, et al.
Publicado: (2013)

Development of interferon γ-based immunocytokines targeting renal cancer
por: Chen, Peirong, et al.
Publicado: (2013)

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
por: Rekers, Nicolle H., et al.
Publicado: (2018)

Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy
por: Casadesús, Ana Victoria, et al.
Publicado: (2022)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex
por: Chen, Jihong, et al.
Publicado: (2022)

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
por: Cha, Seung E., et al.
Publicado: (2021)

(89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
por: van Brummelen, Emilie M.J., et al.
Publicado: (2018)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

Anti-angiogenic collagen IV-derived peptide target engagement with α(v)β(3) and α(5)β(1) in ocular neovascularization models
por: Lima e Silva, Raquel, et al.
Publicado: (2023)

In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2014)

Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies
por: Katsumata, Kiyomitsu, et al.
Publicado: (2019)

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
por: Ribas, Antoni, et al.
Publicado: (2009)

Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis
por: Rhodes, Kelly R., et al.
Publicado: (2023)

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
por: Connor, Joseph P, et al.
Publicado: (2013)

Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts
por: Orecchia, Paola, et al.
Publicado: (2015)

Gene delivery for immunoengineering
por: Neshat, Sarah Y, et al.
Publicado: (2020)

L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model
por: Orecchia, Paola, et al.
Publicado: (2019)

Anti-CD70 Immunocytokines for Exploitation of Interferon-γ-Induced RIP1-Dependent Necrosis in Renal Cell Carcinoma
por: Chen, Peirong, et al.
Publicado: (2013)

Affinity of fibronectin to collagens of different genetic types and to fibrinogen
Publicado: (1978)

Synthetic poly(ester amine) and poly(amido amine) nanoparticles for efficient DNA and siRNA delivery to human endothelial cells
por: Tzeng, Stephany Y, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ke17mns7s4cdbu1phjutb6di2n